EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeserbrief

From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity

Yue Feng, Yingze Li, Zhenhao Zhang, Yuxuan Dai, Xingchun Gou, Kejing Lao, Running Zhang

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04781-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Yue Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Shaanxi University of Chinese Medicine, No.1 Century Road, Qindu District, Xianyang, 712046, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Biomarkers, Tumor, Nuclear Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Open Program for College Students of Xi'an Medical University, Young Talent Fund of Association for Science and Technology in Shaanxi, Natural Science Basic Research Program of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SLFN11, a DNA/RNA helicase implicated in replication stress response, has recently emerged as a pivotal determinant of chemotherapy sensitivity across multiple cancer types. The expression level of SLFN11 in various cancers is significantly positively correlated with the sensitivity of cancer cell DNA damage agents. SLFN11 exerts its chemosensitizing effects by RPA-coated single-stranded DNA (ssDNA) at stressed replication forks at stalled replication forks, thereby potentiating the cytotoxicity of platinum agents, topoisomerase inhibitors, and PARP inhibitors. Its roles in inhibiting ATR translation, mediating p53-independent apoptosis, sensitizing towards IFN-γ and enhancing chromatin accessibility also remain investigational. The down-regulation of SLFN11 expression is associated with epigenetic silencing including promoter methylation, histone deacetylation, and the histone methylation. In this paper, we reviewed the recent progress of SLFN11 as predictive biomarker and therapeutic target in multiple cancers including medulloblastoma, prostate cancer, breast cancer, ovarian cancer, lung cancer, head and neck cancer, esophageal carcinoma, gastric carcinoma and colorectal cancer. We also summarized 10 active clinical trials conducting molecular analyses to assess SLFN11's role. By bridging mechanistic understanding with translational opportunities, this review provides a roadmap for leveraging SLFN11 to overcome chemoresistance and advance precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsBiomarkers, TumorNuclear ProteinsHumansAnimalsDrug Resistance, NeoplasmMolecular Targeted TherapyDNA Damage

Stichwörter der Autor:innen

BiomarkerCancersDDAsDrug resistanceSLFN11Therapeutic target

Substanzen

SLFN11 protein, humanAntineoplastic AgentsBiomarkers, TumorNuclear Proteins

Autor:innen und Institutionen

  • School of Clinical Medicine, Shaanxi University of Chinese Medicine, No.1 Century Road, Qindu District, Xianyang, 712046, China.
  • Shaanxi Key Laboratory of Brain Disorders & Institute of Basic and Translational Medicine, Xi'an Medical University, No.1 Xinwang Road, Xi'an, 710021, China.
  • Shaanxi Key Laboratory of Brain Disorders & Institute of Basic and Translational Medicine, Xi'an Medical University, No.1 Xinwang Road, Xi'an, 710021, China. laokejing_jzs@xiyi.edu.cn.
  • Second Department of Encephalopathy, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xiangyang, 712046, China. xyzrn2000@163.com.

Förderung

  • Open Program for College Students of Xi'an Medical University
  • Young Talent Fund of Association for Science and Technology in Shaanxi
  • Natural Science Basic Research Program of Shaanxi Province
  • Science and Technology Innovation Base-Open and Sharing Platform Resources Project of Shaanxi Province
  • Shaanxi Province Innovation Talent Promotion Program
  • Scientific Research Program Funded by Shaanxi Provincial Education Department
  • Open Program for College Students of Xi’an Medical University

Zitieren

APA

Feng, Y., Li, Y., Zhang, Z., Dai, Y., Gou, X., Lao, K., & Zhang, R. (2025). From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04781-w

Vancouver

Feng Y, Li Y, Zhang Z, Dai Y, Gou X, Lao K, et al. From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04781-w

BibTeX
@article{Feng2025,
  author = {Feng, Yue and Li, Yingze and Zhang, Zhenhao and Dai, Yuxuan and Gou, Xingchun and Lao, Kejing and Zhang, Running},
  title = {From predictive biomarker to therapeutic target: the dual role of SLFN11 in chemotherapy sensitivity},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04781-w}
}
Kostenlos starten →